Scrip
MTP pays $105 million up front for extended telaprevir rights
31 July 2009
Ian Haydock
Please Login to read the full article.
31 July 2009
Ian Haydock
ian.haydock@informa.com
Mitsubishi Tanabe Pharma (MTP) has amended its 2004 agreement with Vertex Pharmaceuticals for the development and commercialisation of Vertex's oral hepatitis C antiviral telaprevir in Japan and other Asian markets.
The Japanese firm will pay $105 million on signing for rights to develop...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Vertex exchanges telaprevir milestones for one-time pay-out
- Vertex reports second positive pivotal Phase III study for HCV protease inhibitor telaprevir
- Merck's boceprevir improves cure rates in two pivotal hepatitis C trials
- HGS says US approval of fortnightly Zalbin is unlikely
COMMENT
Other Informa Comment
EVENTS
01 January 1970
London, UK
01 January 1970
San Diego, US
01 January 1970
Providence, Rhode Island, and San Francisco, California
JOB OF THE WEEK
Promote your vacancy here
